



On 4 October 2018, the Comisión Nacional del Mercado de Valores (CNMV), has adopted the following decision:

“To suspend precautionarily, with immediate effect, pursuant to Article 21 of the Royal Decree-Law of 29 December of urgent measures for the adaptation of Spanish law to European Union regulations on the securities market, the trading of Laboratorios Farmaceuticos Rovi, S.A. in the Stock Exchanges and in Sistema de Interconexión Bursátil, the shares and other securities that may give right to their subscription, acquisition or sale, due to circumstances that could disturb the orderly course of transactions on such instruments.

The suspension of trading is executed at the request of Laboratorios Farmaceuticos Rovi, S.A. as a result of the commencement of a placement of newly-issued shares of the company issued for the purposes of a monetary capital increase excluding the pre-emptive subscription right.”



COMMUNICATIONS IN THE FORMAT SET OUT IN TABLE 3 OF  
THE COMMISSION IMPLEMENTING REGULATION (EU) 2017/1005  
of 15 June 2017

FIELD	FORMAT FOR REPORTING
Competent authority	CNMV
Member State of the competent authority	ES
Trading venue operator as initiator of the action	False
Date and time of the publication / communication	2018-10-04T12:30:00.Z.
Action type	Suspension
Reasons for the action	Due to circumstances
Effective from	2018-10-04T12:30:00.Z.
Effective to	
Ongoing	True
Trading venue(s)	XMAD
Issuer Name	LABORATORIOS FARMACEUTICOS ROVI, S.A.
Issuer	95980020140005936480
Instrument identifier	ES0157261019
Instrument full name	LABORATORIOS FARMACEUTICOS ROVI, S.A.
Related derivatives	
Other related instruments	
Comments	